The systems analysis of thrombosis seeks to quantitatively predict blood function in a given vascular wall and hemodynamic context. Relevant to both venous and arterial thrombosis, a Blood Systems Biology approach should provide metrics for rate and molecular mechanisms of clot growth, thrombotic risk, pharmacological response, and utility of new therapeutic targets. As a rapidly created multicellular aggregate with a polymerized fibrin matrix, blood clots result from hundreds of unique reactions within and around platelets propagating in space and time under hemodynamic conditions. Coronary artery thrombosis is dominated by atherosclerotic plaque rupture, complex pulsatile flows through stenotic regions producing high wall shear stresses, and plaquederived tissue factor driving thrombin production. In contrast, venous thrombosis is dominated by stasis or depressed flows, endothelial inflammation, white blood cell-derived tissue factor, and ample red blood cell incorporation. By imaging vessels, patient-specific assessment using computational fluid dynamics provides an estimate of local hemodynamics and fractional flow reserve. High-dimensional ex vivo phenotyping of platelet and coagulation can now power multiscale computer simulations at the subcellular to cellular to whole vessel scale of heart attacks or strokes. In addition, an integrated systems biology approach can rank safety and efficacy metrics of various pharmacological interventions or clinical trial designs. (Circ Res.
D espite gains in detection, stenting, and pharmacology, coronary vascular disease caused >900 000 acute myocardial infarctions and ≈1 in 6 deaths in the United States in 2010. 1 Stroke and coronary vascular disease result in >$315 billion each year in lost productivity and medical costs. Cofactors such as smoking, high cholesterol, obesity, hypertension, diabetes mellitus, and inactivity set the stage for complex thrombotic pathologies. Deep vein thrombosis/pulmonary embolism result in an additional >60 000 deaths per year in the United States. 2 Prevailing flow conditions, vessel wall biology, and blood biology all combine to influence the progression of arterial or venous thrombosis (Table 1 ). In coronary vascular disease, stenotic plaque rupture exposes tissue factor (TF) and collagen to blood triggering the extrinsic pathway of coagulation ( Figure 1 ). Platelets respond to collagen and thrombin to release ADP from dense granules and synthesize thromboxane via cyclooxygenase-1, both of which intensify platelet calcium mobilization. Relatively low subnanomolar levels of thrombin can activate platelets. Relatively high levels of >10 nmol/L thrombin are required to cleave fibrinogen to fibrin under flow although only a small fraction of prothrombin (1.4 μmol/L) is actually converted to thrombin during clotting. Although unnecessary for hemostasis, the contact pathway may enhance thrombosis, possibly through platelet release of polyphosphate. Extreme shear forces exist in stenosed arteries that can cause unfolding of von Willebrand factor (vWF) and shear-induced platelet activation. In contrast, venous thrombosis occurs under low-or no-flow conditions as a result of inflammatory pathways in the blood and the vessel wall.
During thrombosis, many hundreds of unique reactions proceed in space and time at the dysfunctional vessel wall, within activating platelets, on the platelet surface, and in the coagulating plasma. A blood systems biology approach seeks to account for the biology of the vessel wall, platelets, and plasma in a given patient and local hemodynamic context ( Figure 2 ). 4, 5 Computer simulation of blood function can impact drug target selection, preclinical drug testing, patientspecific drug dosing, clinical trial design, biomedical device design, and stratifying patient-specific disease risk. A multiscale approach quantifies the rates and connections of reactive events at various length scales to inform a coherent view of the overall pathological process ( Table 2 ). In seven sections of this article (Platelet Signaling and Function, Thrombin/Coagulation Models, Adhesion Models and vWF, Vascular Hemodynamic and Computational Fluid Dynamics, Multiscale Thrombosis Models, Pharmacological Models and Microfluidic Models of Clot Growth), the kinetic processes at the individual levels of platelets, plasma coagulation, adhesion/vWF biophysics, and hemodynamics can be integrated together into a systems analysis of thrombus formation.
Platelet Signaling and Function

Omics Approaches
The human platelet transcriptome contains >9000 mRNA species 48 comparable with that of megakaryocytes. The human platelet proteome presents ≈4000 unique proteins, most of which have been assigned a copy number per platelet. 49 Although lacking a nucleus, the platelet is rich in mitochondria and has mRNA splicing, micro-RNA, protein synthesis, an immunoproteosome, and caspase-dependent apoptosis. A protein interaction network (PlateletWeb) 50 curated 3628 platelet proteins with 13 652 interactions and 1704 phosphorylations. The platelet kinome contains 229 kinases and 73 phosphatases. Similarly, a platelet metabolic network 51 has been constructed for platelets. Although platelets are unsuited for direct genetic manipulation, numerous genetically modified mouse models have been developed to explore platelet phenotypes in vivo. Cosemans et al 52 12 [P2Y purinergic receptor, type Y12], etc.) slow and reduce clot growth and enhance embolization, as do defects in signaling proteins (Akt2, phospholipase C γ2 , phosphoinositides 3-kinase, Rac1, RhoA, and STIM1) and defects in certain plasma proteins (complement factor 3, factors XI, XII, fibrinogen, vWF, and Gas6). Fortunately, ample correspondence exists between mouse genotype/phenotype linkages and the human biology of clot formation.
The Bloodomics Consortium used platelet RNA expression profiling to explore individual heterogeneity in platelet response to ADP and collagen-related peptide and implicated 63 different genes that influenced platelet responsiveness. 53 
Systems Biology Models of Platelet Metabolism
Platelets have numerous receptors that mediate activation and inhibition (Table 3 ). Direct computer simulation of platelet metabolism is possible when sufficient information is available to define the reaction network and kinetic rate equations (ie, model topology) along with initial conditions and kinetic coefficients (ie, model parameterization). To model these reaction networks, ordinary differential equations (ODEs) are written for the concentration of the ith species C i in the reaction network containing n species, basically answering the question how does the concentration of each species change with time [dC i (t)/dt=F i (C 1 ,...,C n ) for some initial state C i (t=0) for i=1 to n species]. Several models have focused on outsidein signaling through G-protein-coupled receptors. A model of P2Y 1 activation by ADP through G q -mediated signaling and coupled phosphoinositide metabolism required 77 reactions, 132 rate constants, and 70 species to simulate inositol trisphosphate (IP 3 )-mediated calcium release and reuptake. 6, 7 An important modeling constraint is that the resting platelet remains resting until exposed to sufficiently strong stimuli. This homeostasis constraint requires that the initial condition of the ODE system is also a steady state condition. 7 Such an approach can predict resting levels of 50 to 100 nmol/L intracellular calcium that can rise rapidly to ≈300 to 500 nmol/L intracellular calcium within 10 seconds followed by rapid decay to resting levels within 250 seconds. At the single platelet level, signaling may be highly noisy because of stochastic effects expected for low copy number systems (1 nmol/L=3 molecules per platelet). For a given initial condition, a set of kinetic reaction kinetics can be numerically integrated to obtain average dynamics (as displayed by a population of platelets) or can be solved by Monte Carlo simulation to predict single platelet dynamics. For example, the noisy calcium dynamics observed in single activated platelets has a stochastic origin that has been well simulated by Monte Carlo. 6 Similarly, a model that simulates both IP 3 -mediated calcium release and store operated calcium entry via STIM1-Orai1 required a 34 species model to predict calcium mobilization in the presence of external calcium. 8 Computer models of PAR1 and PAR4 signaling can simulate thrombin-induced calcium mobilization, Rap1GTP generation, and associated inside-out signaling to result in granule release and integrin activation. 12 Collagen activation of GPVI results in receptor multimerization and intense and sustained mobilization of intracellular calcium. Recent simulations of GPVI signaling required >20 parameters to predict Syk phosphorylation dynamics. 57 From these studies, it becomes apparent that a fully mechanistic kinetic model of platelet responses to multiple agonists would require on the order 20 to 100 parameters for each signaling input (ADP, thromboxane A 2 , thrombin, etc.). Whereas a complete thrombin generation models typically require <100 kinetic constants and initial concentrations that are fairly well measured and understood, Figure 1 . Physical and biological processes during thrombosis. Blood flow results in a cell free layer near the wall that is enriched in platelets because of margination. Exposure of matrix proteins like collagen and bound von Willebrand Factor (vWF) results in transient capture of platelets via glycoprotein (GP) Ibα, strong activation via GPVI, and firm arrest via integrin activation. Calcium mobilization is central to platelet activation and drives shape change, integrin activation, dense granule release of ADP and serotonin (5HT), and cyclooxygenase-1-dependent thromboxane (TX) A 2 synthesis. Platelet deposition and autocrine-driven aggregation typically proceeds thrombin generation, which is driven by plaque-derived tissue factor (TF) and potentially by contact pathway engagement of FXIIa and FXIa via wall-derived activators or platelet polyphosphate. Thrombin is a potent platelet activator and at higher concentrations drives fibrin formation. In extreme flow typical of stenosis, a full platelet model could require 200 to 1000 parameters, most of which are not yet quantified precisely. In fact, the neural network (NN) model trained to multicomponent activation data required 180 weight factors. Few models in Systems Biology are this massive, which presents many challenges in model validation, parameterization, and training to the patient's own platelets.
Large models with many unknown parameters (initial concentrations or kinetic constants) present a different challenge when compared with ambiguity of model uncertainty (ambiguous or unknown reaction mechanisms). The parameterization challenge has several layers. Different sets of parameters may equally fit the data. This situation is interesting and has been explored in Purvis et al 7 using principal component analysis for efficient search directions dictated by the steady states of smaller modules in the system. In fortunate cases, the available data are highly constraining and forces attention on those unknown parameters that must take on values in a narrow range, indicative of their regulatory importance. In unfortunate cases, a unique set of parameters cannot be found to match the constraining data, thus highlighting (1) potential weaknesses in the model that require additional mechanisms (a symptom of model uncertainty) or (2) the computational challenge of high-dimensional searching. Regardless, high-dimensional and insoluble activators (collagen) to drive intracellular calcium mobilization. Calcium mobilization occurs rapidly through IP 3 -mediated release and store-operated calcium entry (STIM1-Orai1). Dense platelet deposits in clots result in significant ADP and thromboxane and thrombin-driven signaling, often targeted by inhibition of P2Y 12 , cyclooxygenase (COX)-1, and PAR1, respectively. During coagulation, the generation of thrombin (FIIa) is primarily driven by TF/FVIIa (extrinsic tenase) via subsequent engagement of the FIXa/VIIIa (intrinsic tenase) and FXaVa (prothrombinase). Thrombin has significant regulatory control on its own production through activation of FVIIIa, FVa, FXIa, as well as regulation of fibrin through activation of FXIIIa that crosslinks fibrin. Local hemodynamics (inset; reprinted from Taylor et al 3 with permission of the publisher. Copyright ©2013, Elsevier.) can be determined by computational fluid dynamics to define locations with at-risk plaque burden, stenosis, and high wall shear stress. Full systems biology models of platelet activation and coagulation in a patient-specific flow field are directed at simulation of acute coronary syndromes (bottom). AC indicates adenylate cyclase; AP, antiplasmin; APC, activated protein C; ATIII, antithrombin III; catG, cathepsin G; CTI, corn trypsin inhibitor; DTS, dense tubular system; EC, endothelial cell; FDP, fibrin degradation product; GC, guanylate cyclase; GPVI, glycoprotein VI; HMWK, high molecular weight kininogen; HNE, human neutrophil elastase; IP, prostacyclin receptor; MG, macroglobulin; NO, nitric oxide; P2Y purinergic receptor type 2; PAI, plasminogen activator inhibitor; PAR, protease activated receptor; PC, protein C; PLC, phospholipase; PMCA, plasma membrane calcium ATPase; PN2, proteonexin 2; PS, protein S; TM, thrombomodulin; TP, thromboxane receptor; tPA, tissue-type plasminogen activator; and uPA, urokinase plasminogen activator.
by guest on November 8, 2017 http://circres.ahajournals.org/ Downloaded from data sets obtained under many conditions and constraints that measure important species at several times are outstanding for model testing.
High-Dimensional Platelet Phenotyping Methods
Given the responsiveness of platelets to diverse signals present during clotting (Table 3) , various high-throughput 
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methods have been developed to functionally phenotype platelets. The pairwise agonist scanning approach 9 is a 384well plate assay that measures platelet intracellular calcium mobilization in response to all single and pairwise stimulations with agonists used at 0.1, 1, and 10×EC 50 of each agonist. A total of 154 responses using 6 agonists (convulxin, U46619, PAR1-activating peptide, PAR4-activating peptide, ADP, and PGE 2 ) to stimulate GPVI, TP, PAR1, PAR4, P2Y 1 / P2Y 12 , and IP/EP [1] [2] [3] [4] (prostaglandin E receptor type 1-4) were then used to train NN models. NN models are an example of machine learning where measured outputs are predicted from a set of input conditions and trained signal processing nodes linked together, akin to neuron signaling. The NN model is patient specific and was able to predict responses beyond the training set such as response to trinary stimulation, response to 4 to 6 agonists, and responses to sequential stimulation. NN models are ideal for incorporation into multiscale models of thrombosis 40 as will be discussed in Multiscale Thrombosis Models section of this article. Similarly, an average platelet NN was generated for an ensemble of 10 healthy donors (50% men) to predict calcium mobilization dynamics in response to combinations of collagen mimetic (convulxin), thrombin, ADP, thromboxane mimetic, NO donor, and prostacyclin mimetic. 10 The pairwise agonist scanning method has also been extended to monitor single platelet α 2b β 3 activation, P-selectin display, and phosphatidylserine exposure by flow cytometry. 58 Microspot printing of collagen matrix-TF features on glass allows highthroughput testing of blood response to a surface, such as for the determination of TF concentration threshold for robust fibrin production by whole blood under flow. 59 63 involves the aliquoting of stimulants to 96-well plates (which can be stored frozen) followed by testing platelet aggregation in the thawed plates subjected to mixing in a plate reader. This type of assay is particularly sensitive for identifying platelet hypoactivity and associated bleeding risk, but in theory could also reveal hyperactivity and thrombotic risk.
High-dimensional and miniaturized phenotyping tools help quantify platelet signaling, granule release, integrin activation, and retraction. For patient-specific predictions, a quantitative mathematical model needs to meet 2 criteria: (1) match or predict the available training data for a specific patient and (2) predict phenomenon beyond the training data such as clotting rates at venous and arterial flow as measured using microfluidics. Meeting these 2 criteria would represent a first step toward validation of patient-specific models for stratification of disease risk or drug responsiveness. 
Thrombin/Coagulation Models
Evolution requires that blood remains a flowing liquid for oxygen delivery over large length scales, while simultaneously providing intense yet highly regulated and localized responsiveness to vessel disruption by engaging platelet activation and coagulation. As a dynamical system in balance, healthy blood is robustly homeostatic (ie, flowing) and robustly hemostatic. This tense balance is maintained by numerous activators, inhibitors, amplifiers, and feedback mechanisms: the source of consternation for the pharmacologist, clinician, and patient alike seeking to manage thrombotic risk without increasing bleeding risk.
The Most Proximal Triggers of Clotting
The central objective of the coagulation system is to convert prothrombin to thrombin. Platelets are intensely responsive to subnanomolar levels of thrombin, whereas >10 nmol/L thrombin is required to polymerize fibrin robustly under flow conditions. The extrinsic pathway relies on exposure of TF within lipid membranes to bind factor VIIa. Factor VII is the one clotting factor that is cleaved to a significant extent (≈1% of factor VII) in healthy blood although FVIIa remains in a zymogenlike conformation until binding to TF, resulting in enhanced FVIIa activity against FX and FIX. The cellular pathway involves FVIIa binding to activated platelet membrane facilitating FVIIa activity toward FX in the absence of TF, a reaction only relevant during high-dose recombinant FVIIa therapy. Although not required for hemostasis, the contact pathway involves anionic materials (such as DNA, RNA, collagen, polyphosphate, or artificial surfaces) that bind Factor XII, leading to a FXII conformation that can then enzymatically generate FXIIa and FXIa. The contact pathway begins with the activation of FXII to FXIIa on a contact surface. Other factors distal of FXIIa such as FXIa, FIXa, and FVIIIa can be thought as a part of the contact pathway. However, it is important to recognize that FXIa and FIXa can be generated by routes independent of FXIIa (and thus the older intrinsic pathway nomenclature has fallen out of use to some degree). In addition to zymogens in the blood, extremely low levels of active clotting factors likely exist in healthy blood as the blood remains in an idling state (engine running model) as evidenced by detectable level of activation peptides in healthy plasma. Intravascular thrombosis, typically in the absence of bleeding, progresses when attributes of the vessel wall, the blood, and the hemodynamics are pathological (ie, Virchow Triad).
From TF to Thrombin
The kinetic analysis of thrombin generation in purified protein systems, plasma, platelet-rich plasma, or whole blood usually begins by considering the entire reaction network in an isotropic context that lacks spatial gradients and fluid shearing (ie, a test tube). With hundreds of published studies of enzyme kinetics, bottom-up models can accommodate complete definition of reaction pathways and their parameterization (initial concentrations and rate constants). These ODE mathematical simulations encapsulate a modeling philosophy such as ignore platelets, include platelets, complexify, simplify, emphasize regulatory dynamics, validate against real data, or tune the model against real data. For small subnanoliter volumes and low copy number of important proteins (like TF), the clotting reactions can display stochasticity caused by random variations. For stochastic simulation, the kinetic rates of clotting must be solved by Monte Carlo simulation. 17 Table 2 summarizes several computational models of coagulation, many of which are downloadable. For a given set of clotting factor concentrations, some key features of these various models are damping if triggering stimuli are subthreshold, nonlinear sensitivity to initial condition, and nonlinear amplification: Certain regulatory dynamics of coagulation require continual refinement from a modeling perspective such as (1) the precise rates and mechanisms of prothrombinase (FXaVa) inhibition on a platelet surface; (2) the role of FXIa autoactivation; (3) endogenous levels of contact activation within blood (eg, platelet polyphosphate); (4) the role of disulfide isomerases in protein regulation and de-encryption; and (5) the state of blood obtained by phlebotomy versus the in vivo state. Importantly, if a particular molecule such as TF or FXIa is potent at 10 to 100 fM levels, antigenic determinations will lack sufficient sensitivity and specificity; thus, kinetic measurements and kinetic arguments must carry the day. Although adding features and complexity to models is always possible, systems biology approaches should also prioritize key regulatory features that are most important in controlling clotting. Such insights, often from sensitivity analysis 64 can allow the creation of reduced models 65,66 that capture the major features of clotting dynamics with considerably fewer parameters.
Calibrated automated thrombinogram uses a fluorogenic thrombin substrate in plasma (or platelet-rich plasma) that is activated with 1 to 10 pmol/L of TF. 67, 68 For healthy plasma, a lag phase exists for several minutes before a burst of 200 to 400 nmol/L thrombin over a period of 2 to 5 minutes and a decay over the next 10 or 20 minutes. The thrombin signal is ideal for testing computational models of plasma function, 15, 69, 70 especially for bleeding phenotypes. Brummel-Ziedins et al 69 found the calibrated automated thrombinogram assay a reliable metric of hypofunctional thrombin generation because of pharmacological inhibitors (rivaroxaban and warfarin) and, importantly, hyperfunctional thrombin generation in advanced pregnancy. However, the calibrated automated thrombinogram assay does not recreate the accumulating platelet density and spatial gradients that are unique to thrombosis. A plasma-based assay that recreates spatial gradients involves the incubation of plasma against a TF-rich surface. In this assay, an easily visualized fibrin front propagates away from the triggering surface, controlled by diffusion of proteins such as thrombin and fibrin monomer, all amenable to computational analysis of reactiondiffusion. 71 Such thrombin activity and fibrin polymerization fronts typically travel slowly at a rate of ≈3 mm in 60 minutes,
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consistent with simulation. This slow traveling wave propagation is akin to the physics in stagnant blood clotting in a wound site triggered by TF in the wound boundary.
Role of FXIIa and FXIa in Thrombin Generation
The contact pathway has received renewed interest as a therapeutic target to reduce thrombosis. FXIIa deficiency is not associated with a bleeding risk, whereas FXI deficiency results in a bleeding risk (hemophilia C) in some individuals. Mice deficient in FXII display reduced thrombosis in a vessel injury model. 72 To date, most modeling of the contact pathway usually focuses on biomaterial thrombosis 18 or in the diagnostic setting where containers and corn trypsin inhibitor are used. 15 The natural activators of FXII in human pathology during plaque rupture could include DNA, RNA, collagen, and platelet polyphosphate. The kinetics of FXII activation by ruptured plaque are not well established although contact activation can occur in this context. 73 Kuijpers et al 73 showed in a rupture plaque model in Apoe (−/−) mice that FXII also functions at later stages of clotting. In venous thrombosis, neutrophil release of neutrophil extracellular traps that are chromosomal contents with the potential for contact activating activity. 74
Fibrin Generation and Fibrinolysis
With the ability to simulate and predict thrombin generation, the kinetics of fibrin polymerization under stagnant and flow conditions becomes tractable. The generation of reactive monomers that polymerize under isotropic conditions (no gradients) can be solved by Monte Carlo simulation 75 or by numeric integration of ODEs for the formation and consumption of dimers, trimers, and higher ordered species. 20 The rates of protofibril extension, protofibril lateral aggregation, and branchpoint all control final fiber diameter and network branching. 21 Computer simulations predict that flow suppresses fibrin formation above ≈200 s −1 wall shear rate because washout of monomers can occur faster than their incorporation into fibrin. 22 The structural mechanics of fibrin and fibrin-rich clots and consequent effects on clot retraction and embolism rates are experimentally accessible 76 but represent a large computational challenge to predict clot strength based on fibrin-platelet ensembles. The kinetics of fibrinolysis are essential to wound healing, impaired hemostasis, as well as thrombolytic therapy of arterial and venous blockages. Kinetic simulations of thrombolytic therapy and of fibrinolysis allow prediction of lysis front propagation under conditions of diffusive or pressure-driven permeation. [23] [24] [25] [26] Interestingly, concepts of clot porosity, permeability, and intrathrombus protein diffusivity that are critical to thrombolytic therapy 77 are also essential for understanding the progression of hemostatic and thrombotic events.
Adhesion Models and vWF
With systems models of platelet activation and thrombin production, accounting for cell adhesion is required to predict clot growth. Numerous adhesion receptors are operative during thrombosis including: GPIbα/vWF, GPVI/collagen, α 2 β 1 / collagen, α IIb β 3 /fibrinogen, and α IIb β 3 /vWF (Figure 1 ). The proximity of 2 adhering membranes defines the ability of receptors to bind their counterligands. In general, binding events must be sufficiently rapid if they are to capture a platelet from the flow field. As bonds are loaded with hemodynamic forces, the expectation is usually that the bonds break more rapidly, referred to as a slip bond. Bonding that becomes stronger when loaded with force is described as a catch bond and may result by formation of extra points of protein-protein contact as atomic-level conformations at the molecular interface are presumably altered by force. 78, 79 The force to rupture a typical bond depends on loading conditions from the prevailing hemodynamic environment as transmitted through the cell body, typically requiring ≈10 to 100 pN to rupture a single bond between P-selectin-P-selectin glycoprotein ligand (PSGL1), GPIbα/vWF, 80 α IIb β 3 /fibrinogen or α 2 β 1 /collagen 81 for loading rates in the range of 10 2 to 10 4 pN/s. Adhesive dynamic simulations for single platelet capture, 29 single platelet translocation on vWF, 29, 30 or neutrophil rolling have single molecule resolution on molecular length scales and are time-consuming computations that are not feasible for whole clot growth simulations involving hundreds to millions of platelets in a clot. Also, cells are deformable, and platelet membrane tether pulling may significantly affect loading mechanics at pathologically high shear rates. Therefore, simpler adhesion models based on apparent rates 40 of attachment and detachment and the cellular activation state are typically used for clotting simulations under flow.
Von Willebrand Factor
vWF released by endothelium is the largest soluble molecule in blood, reaching sizes of 100 to 1000 nm and molecular weights >20×10 6 MW. As a colloid in the plasma, vWF has a globular conformation and can undergo structural changes when subject to hemodynamic forces. vWF also binds and carries FVIII. vWF is required for platelet capture under arterial shear conditions (wall shear rates >1000 s -1 ). Molecular dynamics simulations of A1 and A2 domains of vWF suggest that the A2 domain obscures the A1 domain from GPIbα binding, unless stretching forces unshield the A1 domain. 82 The linker between the D3 and A1 domains may also interact with A1 domain to modulate GP1bα bonding dynamics. 83 In addition, under the conditions of extreme flows found in stenotic arteries, vWF can undergo elongation and self-association into massive fiber aggregates 84, 85 that have been detected at the end stages of a thrombotic event in vivo. 86 Predictive models of vWF conformation in flow are not yet molecularly resolved, but can be based on a coarse-grained approximation of vWF structure and subunits using concepts from polymer theory. Interaction energies between domains have been assumed (≈0.5-2 K b T) to estimate critical elongational rates (ε crit =500 s −1 ) or critical shear rates γ crit =10 4 s −1 to drive globule-stretch transitions. 27 The development of quantitative descriptions of platelet GPIbα bonding and vWF conformation under the extreme hemodynamic conditions of arterial stenotic thrombosis remains an intensive research challenge.
Vascular Hemodynamic and Computational Fluid Dynamics
Intravascular thrombosis propagates in the presence of local prevailing hemodynamics. Flow affects clotting and clotting affects flow. With flow, the wall shear rate (γ w ) dictates the collision rate of cells with the wall and the wall shear stress (τ w ) dictates the drag forces on adherent clot assemblies. By combination of direct imaging and computational fluid dynamics, the prevailing instantaneous or time-averaged velocity profile can be calculated. Computational fluid dynamics involves numeric solution of the Navier-Stokes equation, which defines force=mass×acceleration for a liquid. With the velocity profile, numerous metrics of the instantaneous or time-averaged flow can be calculated including: γ w , τ w , oscillatory shear index, and fractional flow reserve (FFR). Arterial shear stresses in healthy vessels are pulsatile and typically in the range of 10 to 40 dyne/ cm 2 (time-averaged) but can exceed hundreds of dyne/cm 2 in a narrowed stenotic region. In coronary and carotid vessels, locations with low and oscillatory shear stress are considered atheroprone. 87 In contrast, venous flows are slow (≈100-200 seconds −1 wall shear rate and 1-8 dyne/cm 2 wall shear stress), have steady flow, and may approach stasis (velocity goes to zero) as a high-risk setting for deep vein thrombosis.
Arterial stenotic flows are notable for their extremely high shear stresses, marked pressure drops when >75% stenosis causes angina, helical flows for asymmetrical lesions, recirculation zones distal of the stenosis, and display of turbulence if the Reynolds number > 300 to 400 during certain moments of the pulse cycle. The Reynolds number is defined as Re=ρDV/μ for ρ=density, V=velocity, D=diameter, and μ=viscosity. Whole coronary hemodynamic simulations have emerged as a powerful tool to access vulnerable heart muscle at risk. 35 These pulsatile flow calculations 3 require an estimation of the upstream pressure at the aorta inlet (lumped-parameter heart model) and the downstream pressure caused by coronary microvascular resistance, typically using 1-dimensional (1D) lumped models of the microvascular resistance. Often the FFR can be calculated if the vascular geometry has been measured and a resting flow or hyperemia flow has been estimated or induced. A stenosis or thrombosis of only 50% results in high shear stresses and high velocities as blood jets through the narrowing; however, such a narrowing offers little resistance to blood flow, with few symptoms of angina. Only as a stenosis or a clot grows in the coronary artery to severely reduce the available lumen (>75% stenosis by both plaque and thrombus) does a significant pressure drop exist across the narrowing to reduce flow rate. Velocities in the severe narrowing may remain pathological until complete occlusion occurs, the onset of acute myocardial infarction, and blood is diverted to other vessels. Severe arterial stenoses cause acceleration and deceleration of blood flow and are associated with pathological wall shear rates that can range from 5000 to >100 000 s −1 (wall shear stresses of 150 to >3000 dyne/cm 2 ). [88] [89] [90] [91] Spatial gradients of wall shear rate (grad γ w ) are tremendous in severe stenosis reaching values of 600 000 seconds −1 /cm for the inlet to a human coronary stenosis. 90 Values for the inlet and outlet of a stenosed carotid arteries are similar (grad γ w =±570 000 seconds −1 /cm).
Patient-specific computational fluid dynamics has been demonstrated for vascular anatomies derived from computed tomographic angiography. The FFR is the critical metric for determining if a stenosis causes ischemia. The FFR calculates the hyperemic flow through the vessel with stenosis to a hypothetical case in which the vessel lacks the stenosis. The FFR can be applied to decisions about risk and the need for coronary intervention (particularly when FFR<0.8). 92 However, the FFR makes no statement about the severity of a potential thrombotic event within the stenosis or the patientspecific response to antiplatelet agents or anticoagulants. The opportunity now exists to combine multiscale systems biology models of thrombosis with patient-specific computational fluid dynamics calculations of coronary artery hemodynamics, as discussed in the next section.
Multiscale Thrombosis Models
The physics and biochemistry of thrombosis exist over several length scales that are coupled. Enzyme kinetics, receptor activation, and signal transduction proceed at the molecular scale. Cell-cell interactions at the micron scale result in the buildup of a clot on the 0.1 to 1-mm scale, while prevailing hemodynamics are driven by coronary and heart scale phenomenon over many centimeters. Similarly, dynamics in vein valve pockets can trigger thrombosis over the length of an entire femoral vein. Diffusion moves proteins and small solutes efficiently over cellular length scales (<100 μm), but transport of species over many millimeters requires bulk flow or pressure-driven permeation across porous clots.
Computer simulations of individual deformable RBCs and platelets in flow can predict the bulk viscosity of blood, the thickness of the near-wall plasma layer, enhanced platelet diffusivity caused by flow, and the drift and accumulation of platelets in the near-wall plasma layer. 5, 31, 32, 93, 94 Modeling blood as a continuum fluid is far more computationally efficient for calculation of complex velocity fields in vessels and does not require detailed descriptions of single-cell dynamics. For simulations of thrombosis that involve single platelets depositing to a growing thrombus under flow conditions, the blood is still often treated as a continuum fluid; however, the near-wall excess concentration of platelets must be calculated or imposed as a way of accounting for the suspension nature of flowing blood.
In an early study, Hubbell and McIntire 95 calculated local concentrations of ADP, thromboxane A 2 , and thrombin in the boundary layer over a thin platelet patch on a surface subjected to flow. This approach was extended 96 to clots that protruded into the flow stream, resulting in solute accumulation in distal recirculation zones. However, these studies were not directed at predicting the flow-dependent clot growth dynamics. Using phenomenological equations relating agonists and platelet activation, Sorensen et al 97, 98 simulated combined platelet deposition and autocrine activation by solving a pseudohomogenous, single-phase continuum model of blood clotting over a reactive surface.
In these early computer models, the generation of thrombin was treated with extremely simplified descriptions of coagulation. The Kuharsky and Fogelson 36 model was one of the first detailed continuum-based descriptions of clotting under flow conditions. The model emphasizes platelet coverage of exposed TF as a means of limiting clot growth. Assuming a thin, well-mixed, and stagnant layer at the surface of the wound, this model predicted a narrowly defined, threshold
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concentration range (10-15 fmol/cm 2 ) over which TF has dramatic impact on thrombin production, as found experimentally 59 at 1 to 10 TF molecules/μm 2 . The model also passed an important test of predicting poor thrombin generation under conditions of severe hemophilia A and B. The Leiderman and Fogelson 37 model was a full partial differential equation model of thrombosis under flow over a TF surface, which calculated spatial gradients of numerous soluble species including platelet-released ADP as the clot grew into the flow field (≈30-μm thick in 10 minutes at a shear rate of 1500 seconds −1 ). These simulations have been extended 38 to include thrombin-feedback activation of Factor XIa, which potentiates clot growth at later times, a phenomenon recently observed experimentally 99 with an inhibitor of platelet polyphosphate (which greatly potentiates thrombin-feedback activation of FXIa). Using various FXIa antibodies and polyphosphate inhibitor, Zhu et al 99 also concluded that platelet polyphosphate function in clots was largely related to thrombin-feedback activation of FXIa and not FXIIa generation.
The importance of spatial gradients within clots as they grow is highlighted by the observation of a core-shell architecture in clots ( Figure 3A ). [100] [101] [102] In both mouse laser injury models and in human clots formed ex vivo under flow, the core is a thin clot region that is immediately adjacent to the damaged vessel wall and contains P-selectin-positive platelets, thrombin, and fibrin. Compared with the shell of P-selectinnegative platelets lacking thrombin and fibrin, the core is highly retracted with a more restricted pore space for protein diffusion (Figure 3B ). 103 The mobility of solutes within porous clots can be simulated using 3D architectures derived from confocal images of in vivo clots ( Figure 3C ) 104 indicating that clots have a tortuosity of 2 to 2.5, meaning protein diffusion is reduced by >50% in the core relative to pure Brownian motion in water. In addition, platelet-fibrin clots formed under flow conditions have an extremely dense structure with a Darcy permeability of 2.7×10 -14 cm 2 , with most of the resistance to pressure-driven permeation caused by platelet packing. 105 Toward patient-specific simulation of clotting, Flamm et al 40 incorporated data-driven models of platelet activation using NNs trained by high-dimensional pairwise agonist scanning. 9 Individual platelet locations were simulated by lattice kinetic Monte Carlo 106, 107 to account for convection, platelet diffusion, and platelet drift to the wall along with capture to collagen or other platelets. Flow over the rough platelet deposit was calculated by Lattice Boltzmann method, and soluble species were determined by finite element method (FEM) solution of partial differential equations for ADP and thromboxane A 2 . In this approach, individual donor platelet deposition rates on collagen were accurately predicted as was the rank-ordered sensitivity to cyclooxygenase-1 inhibition, P2Y 1 inhibition, and IP activation. The approach revealed a single donor whose platelets were insensitive to cyclooxygenase-1 inhibition with platelets resistant to TP activation by U46619, revealing a novel heterozygote V241G point mutation in the TP receptor. Platelet deposition rates were accurately predicted for both venous and arterial flows. This lattice kinetic Monte Carlo approach has been extended (Y. Lu, T. Sinno, and S.L. Diamond, unpublished results, 2016) to include thrombin activation of platelets 10 and thrombin generation at the wall using a validated 76-species ODE model 15 (Figure 4 ). The simulations made accurate prediction of occlusion time in a microfluidic test under constant pressure-drop conditions 108 for whole blood flow over collagen/TF, a key metric for coronary risk assessment.
The Xu et al 41, 109 model deployed a new platelet-explicit simulation in a cellular Potts model. In this approach, each position of discretized space can be occupied by platelet mass, fluid, or other cell types. Thrombin production utilized the Kuharsky and Fogelson 36 model in this approach, and a novel prediction was maximal clot growth at an intermediate flow rate. One limitation of the cellular Potts model is that energy parameters used to make Metropolis Monte Carlo moves do not necessarily correspond to actual physical and measurable quantities. One of the newest computational approaches to be added to the tool set of thrombosis simulation is dissipative particle dynamics (DPD). 42, 110, 111 In DPD, fluid flow is modeled as the motion of mesoscale DPD particles. Similarly, platelets are comprised of DPD particles in the simulation. Each DPD particle is subject to various forces such as repulsive, dissipative, and random (Brownian) forces. Also, the wall can exert an attractive force. Tosenberger et al 42 used DPD-partial differential equation to model platelet deposition and embolization from a surface in the presence of fibrin polymerization. Various force coefficients, reaction coefficients, and time step coefficients must be picked carefully to span the range of observed phenomenon.
Most simulations of thrombosis that incorporate detailed coagulation kinetics and platelet signaling are solved for 2D reaction domains. However, flow over growing clots is 3D. Diffusion occurs in 3 dimensions. Also, clots formed under flow display an elongated, 3D structure under flow. Full 3D simulation is certainly possible with increasingly faster computers and algorithms. Approaches for faster computation include remeshing, coarse-graining, graphical processing unit-based computation, and reduced models of coagulation.
Pharmacological Models
With the ability of predicting thrombin production, platelet activation, and clot growth for human blood triggered to clot, a linkage between drug pharmacokinetics and clot pharmacodynamics is possible. Because the balance between minimizing both thrombotic risk and adverse bleeding events creates a narrow therapeutic window, computational models have been applied to predict optimal dosing for single or combination therapy, target selection for drug discovery, and elucidation of mechanism in complex biochemical networks. With a massive 92-protein (148 interaction) model of coagulation and platelet . This NN model can predict complex platelet responses such as calcium mobilization during sequential exposure to agonists (B) as intracellular calcium is mobilized from a resting level (blue, ≈50-100 nmol/L) to maximum levels (red, ≈0.5-1 μmol/L). A platelet-plasma kinetic model of thrombin production (FIIa) corresponds to a set of ordinary differential equations for 76 species that can be solved for any level of initial tissue factor (TF). When TF is absent the model allows for FXIIa generation as an alternative trigger of clotting (C). Combining the PAS-trained NN model and the platelet-plasma ODE model at the collagen/TF boundary (red) allows full simulation (D) of a thrombotic event under flow (velocity streamlines and shear rate from Lattice Boltzmann simulation) where all platelet positions are known (via Monte Carlo), along with prevailing concentrations of ADP, thromboxane, and thrombin in the clot and in the boundary layers just outside the clot (from finite element simulation of convection-diffusion partial differential equation [PDE] equations). ATIII indicates antithrombin III; CVX, convulxin; PAR, protease-activated receptor; PGE, prostaglandin E; PK, prekallikrein; and TFPI, tissue factor pathway inhibitor. 46 searched for reactions in the network that displayed the largest degree of druggability with respect to the control of clotting. They ranked the 25 most fragile reactions that present themselves as most druggable. Both Factor Xa and thrombin were identified as the most fragile points for targeting, exactly consistent with the development of the new class of direct Xa inhibitors and direct thrombin inhibitors. In contrast, FVIIIa and FIXa were more robust in the sensitivity analysis and thus less optimal for targeting with inhibitors, consistent with the bleeding risk of hemophilia A and B. In comparing 2 different direct FXa inhibitors, the dose-response curve of prothrombin time with drug concentration is sensitive to rivaroxaban, but not to apixaban. Using the Jones and Mann 112 model expanded to include reactions for the direct FXa inhibitor drugs, Jourdi et al 43 found that the on-rate for drug association with FXa was the likely underlying cause of this variance between the 2 drugs. In a similar approach to understand re-FVIIa hemostatic therapy in different hemophilias, the Hockin et al 14 model was used 44 to predict clotting times and thrombin production as a function of FVIIa concentration in normal blood and blood deficient in FVIII, FIX, FVII, or TFPI. FVIIa was shown to accelerate the onset of clotting with less effect on the maximal amount of thrombin generated.
Microfluidic Models of Clot Growth
The rate of clot growth for a given blood sample can be followed ex vivo using microfluidic devices that allow a defined flow field and defined surface for triggering the clotting event. 76 For in vitro research, drawn blood is often treated with corn trypsin inhibitor, either at low doses to allow some contact activation or higher doses to more fully prevent the function of FXIIa. 99 Microfluidic devices use small blood samples that are perfused through a defined geometry. These devices have been used to test blood from hemophiliacs, 113, 114 trauma patients, 115 and individuals taking combinations of antiplatelet agents such as nonsteroid anti-inflammatory drugs with aspirin. 116 Microfluidic experiments can be run under conditions of strong contact activation using kaolin/collagen surfaces, 117 strong extrinsic activation using TF-coated collagen, 108 or full anticoagulation of thrombin production to study only platelet function. 40 Numerous pharmacological agents 118-120 that target P2Y 1 , P2Y 12 , cyclooxygenase-1, re-VIIa can be tested using microfluidics to allow a functional determination of drug potency under defined flow conditions. Typically for TF-triggered clotting of flowing whole blood on a collagen surface, platelet accumulation will lead to dense deposits that grow >60-μm thick within 300 seconds with fibrin forming subsequently after ≈1 to 2 minutes in a location close to the surface where the TF and thrombin resides in the experiment. 99, 101, 102, 108 More pathological flow regimes with extreme shear stresses 121, 122 can be created with microfluidic devices, especially for studies focused on vWF structure/function. 84, 85 Microfluidic studies with human blood provide data sets that allow the testing of multiscale computer simulations ( Table 2 ) of platelet function, thrombin, and fibrin generation and alterations of the local flow field during the clotting event. Such computer simulations, once validated, can then be useful to predict phenomenon within the human body that are difficult to observe quantitatively in real time.
Summary
Using individual models of platelet activation, coagulation cascades, cell adhesion, vWF structure/function, and regional hemodynamics as discussed in the previous sections, multiscale models of thrombosis can predict clot morphology and growth rate. 4, 5 In addition to helping to evaluate pharmacological options, modeling of thrombosis may be helpful in predicting cardiovascular device performance such as stents 47 where in vivo observation of slowly evolving thrombotic processes may be difficult. Multiscale calculations rely on kinetic information at the molecular, cellular, and tissue (whole vessel) length scale and the millisecond to many minutes time scale. These calculations challenge the fastest computers available and continually push the boundaries of algorithm development. Common numerical tools are finite element method, immersed boundary elements, lattice Boltzmann, Monte Carlo, and dissipative particle dynamics ( Table 2 ). Simulations of multicomponent spatial gradients from the damaged wall, across the clot, and into the flow are computationally intensive. Simulations of high-velocity, pulsatile reactive blood flows and 3D phenomena over tissue scales of the coronary vasculature are also computationally expensive. With ≈50 years of accumulating computing power and blood research (>10 5 publications in PubMed for blood coagulation), several laboratories have begun to attack the challenge of systems analysis of thrombosis (>350 publications in PubMed for blood coagulation simulation). In combination with genomics, high-dimensional phenotyping, biomarker surveillance, and imaging, systems biology seeks to provide an integrative framework for the clinician treating patients with thrombotic disorders.
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